3 April 2017
Oncimmune Holdings plc - Appointment of Senior Vice President, Market Access & Reimbursement
Appointment of Senior Vice President, Market Access & Reimbursement
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces the appointment of Shane Smith as Senior Vice President, Market Access & Reimbursement Oncimmune (USA).
Shaneis a commercial leader with more than 15 years’ experience within market access, reimbursement and sales management. He has extensive knowledge of the US market and a proven track record in sales force development, training, government accounts, Managed Care Organisations and laboratory contracting. Shane is highly experienced in molecular diagnostic contracting with national, regional and local health sales plans, as well as reference laboratories and hospital systems of all sizes. In addition, he has successfully managed several high dose immunotherapy centres focused on oncology. His experience also covers recruitment, managing and developing field based talent, conducting coaching, training, and providing directional leadership for both diagnostic and therapeutic products.
Most recently, Shane was Vice President, Market Access & Reimbursement, Lineagen, Inc. in Salt Lake City, UT where he focused on coverage and value-based reimbursement for Lineagen’s portfolio. He developed and executed Lineagen’s market access and payor strategies for its optimized chromosomal microarray test and its gene sequencing test. Prior to Lineagen, Shane led Market Access, Payer Markets, & Reimbursement for KEW Group where he managed reimbursement contracts and billing policies, working with organisations, business partners, institutions, commercial and government payors to establish coverage and value-based reimbursement for their proprietary next-generation sequencing solid tumor gene test. Earlier in his career, Shane held multiple sales roles with Prometheus Laboratories as well as Novartis Pharmaceuticals Corp.
“I am delighted to welcome Shane to Oncimmune. His appointment means that we have now completed the management team development we outlined at the time of our IPO. With Shane’s wealth of experience adding to our already strong team, I am even more confident we have the necessary sales structure in place to fully exploitourEarlyCDT®-Lung testas well as looking to develop and bring to market other diagnostic tests from across the EarlyCDT® platform.”
Geoffrey Hamilton-FairleyCEO of Oncimmune
“EarlyCDT®-Lung has the potential to detect cancer up to four years earlier than other methods and I hope to use my previous experience in commercialising multiple diagnostic devices to make sure that this test becomes commercially available to as many patients and payors as possible. I am excited about my future at Oncimmune and look forward to sharing in its success.”
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Giles Balleny, Dominic Wilson
+44 (0) 203 829 5000
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
+44 (0) 20 3709 5708
Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company’s first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.
Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com